. They showed greater improvement on the chest radiograph at discharge, measured as the fall in the maximum dimension of the pleural collection (6.0 (2.7) cm versus 3.4 (2.7) cm; difference 2.9cm, 95% CI 0.3 to 4.4; p<0.05) (Thorax 1997;52:416-421) 
S66
Sahn pyema, from the Greek meaning accumulation of pus in ultimately leading to cell death. These pathophysiological changes result in pleural fluid acidosis, a body cavity, represents the end stage of a complicated parapneumonic effusion. The optimal approach to the a low glucose concentration, and an increased LDH concentration. 12 13 Thus, the typical pleural fluid triad diagnosis and management of complicated parapneumonic effusions is controversial because of the of the fibrinopurulent stage of a parapneumonic effusion is a pH of <7.20, a glucose level of <40mg/dl, and an paucity of prospective randomised trials. The availability of new options for management of these effusions further LDH level of >1000 IU/l. 2 10 11 In addition, pleural fluid becomes clottable as plasma proteins leak into the confounds clinical decision making. 7 A 1992 interactive session of an American College of Chest Physicians' pleural space in conjunction with a loss of the fibrinolytic activity of the inflamed pleura resulting in pleural fibrin meeting on management of pleural space infections showed non-uniformity of opinions on treatment. 8 deposition. 14 15 Fibroblasts migrate from the sub-mesothelial connective tissue into the pleural fluid, unimpeded by the injured mesothelial cell barrier. The secretion of glycosaminoglycan and collagen, in concert Pathophysiology of parapneumonic effusions The clinical features of the patient with a parawith fibrin deposition, compartmentalise the fluid into loculations by bridging the two pleural surfaces and pneumonic effusion depends on the stage of the effusion at presentation and can vary from symptoms of limiting lung expansion. 15 At some unknown point during the fibrinopurulent stage the clinician loses the pneumonia only with a small, free flowing, non-purulent, non-infected effusion to severe chest pain, high ability to treat the patient with antibiotics alone and pleural space drainage becomes necessary to prevent fever and systemic symptoms with a classic empyema. The stage of the effusion at presentation correlates pleural sepsis. The natural progression of the parapneumonic effudirectly with the time interval between the onset of pneumonia and physician contact.
sion leads to the final stage, the organisational or empyema stage, over a period of at least two weeks to A parapneumonic effusion is formed when permeability pulmonary oedema fluid moves into the several weeks that results in the formation of either a single thick walled cavity or multiple loculations due to pleural space at a rate exceeding the lymphatic drainage capacity of the parietal pleura. The increased production the continued fibroblast migration and growth into the coagulable pleural fluid matrix. An inelastic pleural of pleural fluid results from neutrophil induced endothelial injury of the parenchymal, subpleural and pleural "peel" inhibits pleural space drainage as well as lung expansion. The fluid that is found at thoracentesis in vessels. The proteinaceous fluid that moves from the intravascular to extravascular space increases the parthis stage is classic empyema fluid which is pus (a thick, whitish-yellow, opaque coagulum) that always requires enchymal interstitial pressure and drives fluid between visceral pleural mesothelial cells into the pleural space.
drainage. Pus assumes its specific character because of coagulability of pleural fluid, the abundance of cellular Presumably in most pneumonias pleural fluid production increases, but the excess fluid produced is debris, and fibrin and collagen deposition. Bacteria tend to persist in empyema fluid because of the decreased removed rapidly by normal functioning parietal pleural lymphatics not allowing a clinical pleural effusion to bacterial opsonisation from complement depletion and pleural fluid acidosis. 16 An empyema rarely resolves form. It is probable that only when the parietal pleural stoma become dysfunctional or non-functional because spontaneously; it may herald its presence by draining through the chest wall (empyema necessitatis) or into of mesothelial cell swelling or fibrin occlusion does fluid accumulate to a degree that allows clinical detection. 9 the lung (bronchopleural fistula).
Pleural fluid in the exudative stage does not need The earliest parapneumonic effusion, typical of the exudative (capillary leak) stage, is characterised clinically drainage while an empyema always needs to be evacuated. The real dilemma facing the clinician is how best by an ipsilateral, small, free flowing, turbid exudate with a moderate number of neutrophils. The biochemistry to manage the patient in the fibrinopurulent stage of a parapneumonic effusion. Some of these patients can be of this effusion is a reflection of the pneumonia per se and not pleural space infection. Therefore, the pleural managed with antibiotics alone, while others require pleural space drainage which can be accomplished by fluid pH is typically >7.30, the glucose level is >60mg/ dl, and the lactate dehydrogenase (LDH) concentration several methods including serial therapeutic thoracenteses, standard chest tubes, or image guided small is <500 IU/l. 2 10 11 If the pneumonia is treated with appropriate antibiotics at this stage the effusion is unlikely bore catheters with or without fibrinolytic agents, empyectomy and decortication by thoracoscopy or standto progress to the second or fibrinopurulent stage.
However, if the pneumonia remains untreated, most ard thoracotomy, or open drainage. commonly due to delayed patient presentation, endothelial injury becomes more severe and widespread and a larger volume of pleural fluid is formed. Without the Features that suggest the need for pleural space drainage inhibition of antimicrobial agents, bacterial multiplication in the lung is unchecked and bacteria move
The rapid identification of patients likely to develop complicated parapneumonic effusions should improve from the lung interstitium into the pleural space and eventually overwhelm the capacity of the intrapleural clinical outcome by allowing early pleural space drainage. It is unlikely that common clinical parameters such phagocytes (neutrophils and macrophages) and parietal pleural lymphatics and become persistent, resulting in as the patient's age, peripheral blood leucocyte count, peak temperature, presence or absence of pleuritic chest a positive pleural fluid Gram stain and culture. This fibrinopurulent (bacterial invasion) stage typically ocpain, or number of lobes involved with pneumonia can differentiate between those parapneumonic effusions curs several days following the initial pleural fluid formation and is characterized by an absolute increase in that would benefit from pleural space drainage and those that can be treated with antibiotics alone. 2 17 pleural fluid neutrophils, which have an increased burst in metabolic activity during phagocytosis, resulting in There are, however, clinical features, chest radiographic, ultrasound, and chest CT findings, and pleural increased glucose utilisation and increased production of glucose end products, carbon dioxide and lactic acid, fluid characteristics that suggest that a parapneumonic group.bmj.com on June 19, 2017 -Published by http://thorax.bmj.com/ Downloaded from effusion has a high likelihood of requiring drainage. The   All studies with three or more patients using strepclinical features that suggest the need for pleural space drainage include prolonged symptoms prior to pretokinase or urokinase in the treatment of complicated parapneumonic effusions and empyemas are shown in sentation, anaerobic infection, 18 the combination of leucocytosis, anaemia and hypoalbuminaemia, 19 failure tables 1 and 2, respectively (virtually all of the studies cited are uncontrolled case series). In general the studies of clinical response to antibiotic therapy, 20 and virulence of the pathogen. 4 21 22 Chest radiographic and CT findshow a "good success" rate in the treatment of these complicated parapneumonic effusions in the pleural ings that suggest the need for pleural space drainage include an effusion of >40% of the hemithorax, 19 the space. However, the assessment of treatment in these uncontrolled case series is largely determined by patient presence of an air fluid level, 18 loculation, 2 11 17 23 multiple loculations, the size of the loculations, pleural enselection, especially the timing of the initiation of therapy to the stage of evolution of the parapneumonic effusion. hancement or pleural thickening on contrast CT scan, 24 25 and septations, fibrin strands, and necrotic As can be stated for all treatment modalities of parapneumonic effusions, the earlier that a specific treatdebris 26 27 on ultrasonography. Pleural fluid characteristics that suggest an increased likelihood that a ment is instituted the more likely the outcome will be successful. For example, early antibiotic therapy will parapneumonic effusion requires drainage include purulent fluid (always requires drainage), a positive Gram not only tend to prevent a parapneumonic effusion but will tend to prevent the progress from a simple stain or culture, 18 a low pleural fluid pH (<7.30 or 7.20), low pleural fluid glucose (<40mg/dl), and a high uncomplicated effusion to a complicated parapneumonic effusion or empyema. Furthermore, early LDH concentration (>1000 IU/l). 2 10 11 17 28-30 drainage of a free-flowing, complicated parapneumonic effusion (by biochemical parameters) will tend to prevent loculation and progression to an empyema. Likewise, thoracoscopy is likely to be effective if used early Methods of pleural space drainage in the fibrinopurulent stage of a parapneumonic effusion The pleural space can be drained by standard chest and less likely to be effective in a chronic empyema. tubes, small bore, radiologically guided catheters Fibrinolytic therapy is also more likely to be successful (usually 8-14 F), thoracoscopic debridement, pleural early in the fibrinopurulent stage of parapneumonic irrigation and chest tube placement, standard thoraeffusion and unlikely to be successful in an organised cotomy with empyectomy and decortication, and open empyema cavity when mature fibrin adhesions and a drainage with rib resection. It would be advantageous visceral pleural peel have developed. to the patient with a complicated parapneumonic effuThe key to successful fibrinolytic drainage of comsion or empyema from the standpoint of morbidity and plicated parapneumonic effusions is correct placement cost to be treated by closed drainage with either a of tubes or catheters with radiological guidance early in standard chest tube or small catheter, in lieu of a the evolution of the parapneumonic effusion, followed more invasive surgical procedure such as thoracoscopy, by frequent monitoring (more than once daily) of tube standard thoracotomy, or open drainage. The major placement and fibrinolytic effectiveness by assessing the reasons for failure of tube drainage are tube malposition, volume of tube drainage and immediate re-instillation tube obstruction by viscous fluid, and multiple pleural of the fibrinolytic agent if necessary. In the properly space loculations. Both tube obstruction and a multiselected patient, attention to detail using a strict protocol loculated pleural space has generated interest in will be critical in determining a successful outcome. intrapleural fibrinolytic treatment of complicated parapneumonic effusions during the past half century.
    
There has only been one randomised controlled trial evaluating an intrapleural fibrinolytic in the management of complicated parapneumonic effusions which Fibrinolytic therapy Tillet and Sherry 31 in 1949 first reported the use of forms the index article of this review. In this study Davies and associates 47 studied 24 patients with community fibrinolytic agents in 23 patients who had either acute fibrinous pleurisy, bacterial empyema, or haemothorax. acquired pneumonia and parapneumonic effusions (13 of the 24 patients had either frank pus or culture or Their patients received intrapleural instillation of both streptokinase and desoxyribonuclease that resulted in Gram stain positivity (empyema), while the other 11 cases had a pleural fluid pH of <7.10, LDH contransient pleural fluid fibrinolysis and proteolysis. They also demonstrated depolymerisation of the nucleocentration of >1000 IU/l, and pleural fluid/blood glucose ratio of <0.25 with loculation or septation of pleural fluid protein in the exudate. When toxic manifestations of the drug occurred they were limited to transient febrile on chest CT scanning and ultrasonography, respectively (complicated parapneumonic); tables 1 and 3). Pleural reactions and malaise. Subsequent investigations in small numbers of patients with complicated parafluid was drained with a 14 F catheter and antibiotics were given as a standard antibiotic regimen or guided pneumonic effusions reported improvement in clinical outcome. However, the initial enthusiasm for intraby culture. Twelve patients were randomised to receive intrapleural streptokinase, 250 000 U daily, and 12 pleural fibrinolytics waned because of significant systemic adverse effects until Bergh and colleagues, 32 using patients were randomised to receive the same volume of saline daily for three days. The authors found that a purified streptokinase, reported chest radiographic improvement in 10 of 12 patients with empyemas withthe streptokinase group drained more pleural fluid both during the three days of treatment and during the overall out the need for thoracotomy and without significant adverse effects. Since that time there have been a plethdrainage period. In addition, the streptokinase group showed a greater improvement on the chest radiograph ora of case series using streptokinase and urokinase for initial drainage of the pleural space and for treatment and overall reduction in pleural fluid collection size at discharge. There was no biochemical or clinical evidence of failed chest tube or small catheter drainage, obviating the need for surgical intervention.
of systemic fibrinolysis. Surgery was required in three patients in the control group and in none of the patients the study streptokinase (23 patients) was used. The same physicians were responsible for patient care during in the streptokinase group.
S68

Sahn
Chin and Lim 45 reported on 52 patients (40 with the entire study with a consistent approach to initial empiric antibiotics, indications for further intervention, empyema and 12 with complicated parapneumonic effusions) who were studied prospectively over a five and eventual hospital discharge. Streptokinase was administered intrapleurally in a dose of 250 000 U in year period (tables 1 and 3) . The same criteria used to define empyema and complicated parapneumonic 100ml of normal saline daily with tube clamping for four hours. The total number of doses of streptokinase effusion were used as in the study by Davies and colleagues. In patients with large dependent pleural effuwas determined by patient response. A significantly larger volume of pleural fluid was drained from patients sions, a 24 F chest tube was inserted at the bedside; in patients with multiloculated or non-dependent loculated in the streptokinase group (mean (SD) 2.0 (1.5) l) than in the drainage group (1.0 (1.0) l). There were no effusions, a 7-12 F pigtail catheter was placed under ultrasound guidance. During the first 2.5 years of the significant differences between the two treatment groups in time to defervescence, hospital stay, need for surgical study pleural space drainage alone was the treatment modality (29 patients) and during the last 2.5 years of intervention, or mortality.
group.bmj.com on June 19, 2017 -Published by http://thorax.bmj.com/ Downloaded from A small randomised trial compared chest tube drain-1 and 3). Eligible patients had to have either loculated pleural effusions or a pleural fluid pH of <7.20. Twelve age with intrapleural streptokinase and video-assisted thoracoscopic surgery (VATS) for the treatment of comof the 20 patients had positive bacterial cultures, most of which were anaerobic or microaerophilic organisms. plicated effusions or parapneumonic empyemas 48 (tables
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Patients were randomised to receive either chest tube 24 hours prior to instillation. A significant increase in the mean daily pleural fluid drainage was seen after either drainage with streptokinase (n=9) or VATS (n=11). Patients randomised to tube thoracostomy with strepdrug instillation compared with the volume drained in the 24 hours prior to treatment; however, there was no tokinase had a 36 F chest tube placed under the supervision of a pulmonary fellow or attending and difference between streptokinase and urokinase. High fever (39-40°C) was seen in two of the patients on appropriate placement confirmed by chest radiography. Streptokinase (250000 U in 100ml of normal saline) streptokinase. The cost of the urokinase was twice that of streptokinase, with the mean hospital stay being about was instilled intrapleurally and the tube clamped for four hours. Each patient received three daily doses of 10 days in both groups. In this comparative study both fibrinolytic agents were effective adjuncts in the streptokinase. Following the last dose of streptokinase the patients were evaluated for success using the folmanagement of parapneumonic effusions. lowing criteria: adequate drainage was defined as the resolution of >50% of the original volume of pleural fluid on chest radiography; defervescence to a temperature Intrapleural streptokinase in experimental empyema <38°C; and a peripheral leucocyte count of <11000/ l. The streptokinase failures were referred to thoracic Strange and colleagues 56 studied the effect of intrapleural streptokinase compared to saline control in a surgery for additional treatment. The streptokinase successes were followed until chest drainage was <100ml rabbit model of empyema. Streptokinase or saline was instilled daily for a total of three days immediately after per day, at which time tubes were removed and the patient discharged. Patients randomised to VATS went bacterial inoculation of the pleural space. At day 4 following bacterial inoculation the streptokinase treated immediately to surgery without prior chest tube placement.
animals had a significantly increased amount of pleural fluid and fewer pleural adhesions than the saline treated Based on the study criteria, the VATS group had a significantly higher primary treatment success, fewer control animals but comparable amounts of visceral and parietal pleural thickening. No evidence of systemic days on chest tube drainage, and shorter hospital stays. There was a trend for a lower hospital cost in the VATS fibrinolysis was observed one hour after intrapleural streptokinase instillation. The investigators attempted group. All streptokinase treatment failures were salvaged by VATS and none required thoracotomy. The problems to prevent fibrin deposition before a pleural peel was established, yet failed to completely prevent pleural with this study are the small sample size, the question of adequate chest tube placement by house officers at adhesion formation, although the number of adhesions was significantly less than in the control group. the bedside, uncertainty of chest tube position judged only by standard chest radiography, the short duration A possible explanation for the failure to completely prevent pleural adhesions is the rapid binding of strepof streptokinase treatment, and the strict radiographic criteria for success. It is possible that more frequent or tokinase within an inflamed pleural space. While the half life of streptokinase intravascularly is 15-30 minutes, 57 prolonged use of streptokinase would have resulted in a better outcome. It appears that the "deck was stacked" it is probably shorter in the inflammatory pleural space. Streptokinase normally binds to plasminogen and the against the streptokinase group because of the aforementioned problems. The cost trend was greater for modified plasminogen complex is autocatalytically converted to plasmin. The proteolytic activity of plasmin the streptokinase group because of the addition of the five VATS procedures.
on fibrin, however, can be blocked by a number of protease inhibitors such as 2 -macroglobulin and 2 -A randomised study compared the efficacy, safety profile, and cost of two fibrinolytic agents in the treatantiplasmin found in high concentrations in the inflamed pleural space. 14 The increased procoagulant activity and ment of complicated parapneumonic effusions. Bouros and co-workers 46 studied 50 consecutive patients with high concentrations of plasminogen activator inhibitor 1 and plasminogen activator inhibitor 2, which have complicated parapneumonic effusions 39 or empyema 11 who were randomly allocated to receive either strepbeen found in empyema fluid, 14 may explain the progressive fibrin deposition that can occur between 24 tokinase (25 patients) or urokinase in a double blind fashion (tables 1, 2 and 3). Criteria for inclusion inhour streptokinase dosing. It is possible that an increased frequency of dosing would increase the success of fibcluded multiloculated complicated parapneumonic effusions or loculated empyemas confirmed by CT scanrinolytic agents. It is unclear, in the experimental study, why strepning, ultrasound, or both and failure of drainage via tube thoracostomy (<70ml during the previous 24 hours).
tokinase produced an increased volume of pleural fluid. Streptokinase alone did not produce demonstrable All patients had pleural space drainage with a 28 to 32 F chest tube. Twenty five patients received 250000 effusions while streptokinase, in the setting of a noninfected inflammatory pleurisy, did produce large effu-U streptokinase in 100ml of normal saline and 25 received urokinase 100000 U in 100ml normal saline.
sions. The possibility that pleural fibrinolysis resulted in an increased volume of inflammatory fluid entering Chest tubes in both groups were clamped for three hours following instillation and re-opened to suction. the pleural space from the visceral or parietal pleura while not affecting the patency of the pleural stoma Streptokinase or urokinase was re-instilled if, on ultrasound or CT scanning, a persistent pleural effusion was might explain these findings. seen and the amount of pleural fluid drainage was <50ml during the previous 24 hours. Clinical and radiological improvement was noted in all but two patients in each Systemic fibrinolytic activity of intrapleural streptokinase group who required surgical intervention. Mean (SD) instillations were 6 (2.7) in the streptokinase group and
The most comprehensive study of the systemic fibrinolytic effect of intrapleural streptokinase was recently 5.9 (2.1) in the urokinase group. The chest radiographic improvement score was the same in both groups. The published by Davies and colleagues 58 who studied the systemic fibrinolytic activity of two intrapleural streptomean volume of pleural fluid drained during the first 24 hours after instillation was significantly increased in kinase regimens. Eight patients received a single dose of 250 000 U of intrapleural streptokinase and an adboth groups compared with the volume drained in the group.bmj.com on June 19, 2017 -Published by http://thorax.bmj.com/ Downloaded from ditional eight received serial doses of 250 000 U every and the urokinase dose was 450 000 U. It is possible that the patient's severe hypoxaemia resulted from the 12 hours for three days (total dose 1.5 million units). Each patient had the streptokinase retained in the pleural effect of the products of fibrinolysis on the pulmonary circulation leading to a capillary leak pulmonary oedcavity for two hours. Prothrombin time, activated partial thromboplastin time, thrombin time, fibrinogen and Dema. Alfageme and Vaquez 63 reported a patient who developed ventricular fibrillation following intrapleural dimer levels were measured before intrapleural administration of streptokinase. These end points were urokinase. Mild anaphylactoid reactions after intravenous urokinase have been reported but occasionally then re-measured 24 hours after streptokinase in the single dose group and at 24, 48 and 72 hours in the these reactions may be severe. 64 65 Urokinase has not been found to be antigenic but urokinase can directly group receiving serial doses. There were no physiological or statistical differences in any of the indices after stimulate mast cells and basophils to release histamine and serotonin, causing vasodilatation and vascular peradministration of intrapleural streptokinase. Intrapleural streptokinase, even in a dose of 1.5 million units, meability which can lead to hypotension and shock. 64 Histamine is involved in the enhanced arrhythmodid not cause significant activation of the systemic fibrinolytic system. genicity seen during experimental anaphylaxis by decreasing the threshold for ventricular fibrillation and could have resulted from an anaphylactoid reaction. It is possible that a high single dose and prolonged dwell Adverse effects of fibrinolytics Streptokinase has been reported to be antigenic and time might increase the risk of excess systemic absorption and systemic fibrinolysis. It would appear leads to antibody formation. Re-exposing patients to these agents may cause hypersensitivity or anaphylactoid prudent not to use a single dose of streptokinase of >250 000 U or a single dose of urokinase of >100 000 U reactions. These would be more likely to occur following intravenous administration but could conceivably occur and to keep dwell times to below four hours. It may also be advisable to pretreat patients with acetafollowing intrapleural administration. Lee and colleagues 59 found that antibodies to streptokinase were minophen and diphenhydramine prior to intrapleural fibrinolytics as has been recommended prior to intraraised from four days to at least 54 months following the initial administration of streptokinase intravenously.
venous urokinase. 64 The potential for serious adverse effects would therefore exist following re-exposure to streptokinase during this time period. Major haemorrhage has been reported in a 36 year old Conclusion A single randomised controlled trial of intrapleural man following instillation of 500000 U of streptokinase intrapleurally and clamping of the chest tube for six streptokinase has shown that pleural drainage was enhanced, the chest radiograph was improved, and surgery hours. 60 This patient drained 1500ml of bloody fluid, developed haematuria, gastrointestinal bleeding, pulwas avoided with streptokinase without causing local haemorrhage or systemic fibrinolysis. Intrapleural strepmonary haemorrhage and epistaxis, in addition to oozing from puncture sites. Eleven hours after streptokinase tokinase and urokinase are equally efficacious in treating complicated parapneumonic effusions and empyemas the PT and PTT were 28% and 14% greater than before streptokinase. A single patient developed severe pleural and may reduce the need for more invasive surgical procedures. Streptokinase can be associated with high space haemorrhage following intrapleural streptokinase (exact dose not recorded) one month following rib fever and allergic reactions, while urokinase has rarely been associated with severe adverse effects. However, fractures. 61 Frye and colleagues 62 reported acute hypoxic resurokinase is approximately twice the cost of streptokinase. There has not been a randomised trial of piratory failure following both streptokinase and urokinase given 24 hours apart for treatment of a loculated intrapleural fibrinolytic therapy versus VATS with an adequate number of patients. A large multicentre trial haemothorax. The streptokinase dose was 250 000 U LEARNING POINTS * Fibrinolytic agents are a useful adjunct in the management of complicated parapneumonic effusions. * Both streptokinase and urokinase are equally effective. * Systemic fibrinolysis and bleeding complications are rare events. * In the only randomised controlled trial, in which streptokinase was compared with saline control, the streptokinase group showed an increased volume of pleural fluid drainage during the treatment phase and, overall, an improved chest radiograph and no need for surgery. * Intrapleural fibrinolytics, if used early in the fibrinopurulent stage of a parapneumonic effusion, may obviate the need for VATS or thoracotomy. * A large multicentre randomised trial comparing a fibrinolytic and VATS early in the fibrinopurulent stage of a parapneumonic effusion is needed to determine the optimal management of these patients.
